DE1617661A1 - Verfahren zur Herstellung hochreiner Gonadotropine auf chromatographischem Wege - Google Patents
Verfahren zur Herstellung hochreiner Gonadotropine auf chromatographischem WegeInfo
- Publication number
- DE1617661A1 DE1617661A1 DE19661617661 DE1617661A DE1617661A1 DE 1617661 A1 DE1617661 A1 DE 1617661A1 DE 19661617661 DE19661617661 DE 19661617661 DE 1617661 A DE1617661 A DE 1617661A DE 1617661 A1 DE1617661 A1 DE 1617661A1
- Authority
- DE
- Germany
- Prior art keywords
- ion exchange
- activity
- exchange material
- sephadex
- gonadotropins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000006771 Gonadotropins Human genes 0.000 title claims description 22
- 108010086677 Gonadotropins Proteins 0.000 title claims description 22
- 239000002622 gonadotropin Substances 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 18
- 229940094892 gonadotropins Drugs 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 29
- 229920005654 Sephadex Polymers 0.000 claims description 20
- 239000012507 Sephadex™ Substances 0.000 claims description 20
- 239000007853 buffer solution Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000005342 ion exchange Methods 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 9
- 239000005695 Ammonium acetate Substances 0.000 claims description 9
- 229940043376 ammonium acetate Drugs 0.000 claims description 9
- 235000019257 ammonium acetate Nutrition 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000002523 gelfiltration Methods 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 34
- 229940088597 hormone Drugs 0.000 description 17
- 239000005556 hormone Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- 239000000872 buffer Substances 0.000 description 11
- 239000013543 active substance Substances 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000011149 active material Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000001625 seminal vesicle Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 201000010653 vesiculitis Diseases 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- BPSNETAIJADFTO-UHFFFAOYSA-N 2-pyridinylacetic acid Chemical compound OC(=O)CC1=CC=CC=N1 BPSNETAIJADFTO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- -1 dextran Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- KYWVDGFGRYJLPE-UHFFFAOYSA-N trimethylazanium;acetate Chemical compound CN(C)C.CC(O)=O KYWVDGFGRYJLPE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL6500460A NL6500460A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1965-01-15 | 1965-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1617661A1 true DE1617661A1 (de) | 1971-03-25 |
Family
ID=19792121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19661617661 Pending DE1617661A1 (de) | 1965-01-15 | 1966-01-13 | Verfahren zur Herstellung hochreiner Gonadotropine auf chromatographischem Wege |
Country Status (9)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1717042A1 (de) * | 1963-03-11 | 1972-11-09 | Serono Ist Farm | Verfahren zur Gewinnung von gonadotropen Hypophysenhormonen aus Urin |
| US4033344A (en) * | 1975-04-28 | 1977-07-05 | Jack Owen Reed | Recovery of chorionic gonadotropic hormone from pregnant mares |
| CN114671944A (zh) * | 2022-04-29 | 2022-06-28 | 江苏尤里卡生物科技有限公司 | 一种人绒毛膜促性腺激素纯化方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3119740A (en) * | 1959-04-13 | 1964-01-28 | Armour Pharma | Process for preparing purified follicle stimulating hormone |
| NL124014C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1960-08-08 |
-
1965
- 1965-01-15 NL NL6500460A patent/NL6500460A/xx unknown
- 1965-12-13 US US513561A patent/US3457346A/en not_active Expired - Lifetime
-
1966
- 1966-01-03 GB GB82/66A patent/GB1133071A/en not_active Expired
- 1966-01-07 ES ES0321509A patent/ES321509A1/es not_active Expired
- 1966-01-12 FR FR45646A patent/FR1465014A/fr not_active Expired
- 1966-01-13 DE DE19661617661 patent/DE1617661A1/de active Pending
- 1966-01-14 BE BE675093D patent/BE675093A/xx unknown
- 1966-01-15 DK DK23066AA patent/DK114215B/da unknown
- 1966-01-17 CH CH58066A patent/CH481146A/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK114215B (da) | 1969-06-09 |
| US3457346A (en) | 1969-07-22 |
| FR1465014A (fr) | 1967-01-06 |
| ES321509A1 (es) | 1966-10-16 |
| CH481146A (de) | 1969-11-15 |
| BE675093A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-07-14 |
| GB1133071A (en) | 1968-11-06 |
| NL6500460A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1966-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3520228C2 (de) | Wasserlösliche bioaktive Trockenfeststoffzusammensetzung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE69103755T2 (de) | Wachstumshormonkristalle und verfahren zu deren herstellung. | |
| CH626051A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3039566A1 (de) | Verfahren zur reinigung von interferon | |
| DE2127159C2 (de) | IgG-Immunglobulinfraktion und ihre Herstellung | |
| DE60127100T2 (de) | Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung | |
| DE2440529B2 (de) | Hyaluronidase-Präparat aus menschlicher Plazenta | |
| DE68911693T2 (de) | Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. | |
| DE69720693T2 (de) | Fsh und lh trennungs- und reinigungsverfahren | |
| DE2742150A1 (de) | Verfahren zur herstellung von serumalbumin | |
| DE2732998A1 (de) | Verfahren zur herstellung von serumalbumin | |
| DE3687995T2 (de) | Verfahren zur reinigung von interferon und so hergestellte zusammensetzung. | |
| DE1617661A1 (de) | Verfahren zur Herstellung hochreiner Gonadotropine auf chromatographischem Wege | |
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE2428955C3 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
| DE69229202T2 (de) | Verfahren zur reinigung von menschlichem bcdf | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| DE1940130A1 (de) | Injizierbare Insulinaufbereitungen fuer klinische Zwecke und Verfahren zu ihrer Herstellung | |
| DE2259405A1 (de) | Verfahren zur isolierung von orgotein aus blutzellen | |
| US3674865A (en) | Procedure for obtaining pituitary gonadotropic hormones from urine | |
| EP0180859B1 (de) | Verfahren zur Reinigung sowie Pasteurisierung von Urokinase | |
| DE1617660A1 (de) | Verfahren zur Reinigung von rohem Gonadotropin | |
| DE2333884A1 (de) | Verfahren zur herstellung von gereinigtem albumin und das dabei erhaltene gereinigte albumin | |
| DE2424118B2 (de) | Verfahren zur herstellung von hochreinem kallikrein | |
| DE1802386C2 (de) | Verfahren zur Gewinnung von cytobiotischen Globulinen |